Five Things to Know About Intradialytic Hypertension

Bhanu Prasad\textsuperscript{1}, Juliya Hemmett\textsuperscript{2}, and Rita Suri\textsuperscript{3}

1. Intradialytic hypertension is a paradoxical rise in blood pressure (BP) that occurs specifically during the hemodialysis (HD) procedure.

There are no accepted criteria that define intradialytic hypertension, but several definitions exist:

- An increase in systolic blood pressure (SBP) $\geq 10$ mm Hg during HD (most common definition).\textsuperscript{1}
- Rise in the mean arterial pressure $\geq 15$ mmHg during or immediately post-HD.\textsuperscript{2}
- Any BP rise during HD.\textsuperscript{3}

2. Persistent intradialytic hypertension is common and is associated with poor prognostic factors and increased mortality.

Persistent intradialytic hypertension ($>10$ mm Hg rise in SBP) is reported to occur in 15\% to 30\% of patients treated with HD,\textsuperscript{2,4} and is associated with twofold to fourfold increased risks of hospitalization, all-cause mortality, and cardiovascular mortality.\textsuperscript{5,6} Whether these relationships are causal is not certain, as intradialytic hypertension tends to occur in patients with markers of more severe illness, including older age, lower serum albumin, lower kT/V, lower body mass index, and greater use of antihypertensive medications.\textsuperscript{7} Persistent intradialytic hypertension is likely a marker of cardiovascular risk and vascular stiffness.\textsuperscript{3}

3. Patients with intradialytic hypertension often have high ambulatory BP between dialysis sessions, but this is not universal.

Intradialytic BPs are highly correlated with ambulatory BP between HD sessions, suggesting that patients with intradialytic hypertension are also likely to have uncontrolled ambulatory hypertension.\textsuperscript{8}

4. The causes of intradialytic hypertension are complex and not yet fully elucidated.

Intradialytic hypertension has been observed with equal frequency in patients with normal, low- and high-volume status by bioimpedance,\textsuperscript{4} suggesting volume overload is not the only factor. Factors that increase total peripheral resistance appear to be important, especially in patients with underlying vascular stiffness (Figure 1). Contributing factors thus include volume overload,\textsuperscript{1} sympathetic overactivity,\textsuperscript{9} renin angiotensin aldosterone system,\textsuperscript{10} endothelial dysfunction and relative increase in endothelin 1 to nitric oxide,\textsuperscript{11} administration of erythropoiesis stimulating agents (ESA) during dialysis,\textsuperscript{12} and sodium loading during dialysis.\textsuperscript{13}

5. Several strategies have been proposed but strong evidence is lacking:

\textit{A. Optimize the treatment of essential hypertension.} This includes carefully reassessing the target weight,\textsuperscript{15} the use of appropriate antihypertensives such as beta blockers and angiotensin receptor blockers (see below) and ensuring medication adherence. Extended hours\textsuperscript{16} or frequent HD\textsuperscript{17} may also be considered when circumstances permit.

\textit{B. Consider using a beta blocker with additional alpha blockade activity, such as carvedilol.} In a prospective 12-week pilot study of carvedilol titrated to 50 mg twice daily in 25 patients with intradialytic hypertension, carvedilol was associated with modest improvements in endothelial function, improved BP between dialysis sessions, and reduced frequency of intradialytic hypertension.\textsuperscript{18}

\textsuperscript{1}Division of Nephrology, Department of Medicine, Regina General Hospital, SK, Canada
\textsuperscript{2}Division of Nephrology, Department of Medicine, Foothills Medical Center, Calgary, AB, Canada
\textsuperscript{3}Division of Nephrology, McGill University Faculty of Medicine, Montreal, QC, Canada

Corresponding Author:
Bhanu Prasad, Nephrologist, Division of Nephrology, Department of Medicine, Regina General Hospital, 1440, 14th Avenue, Regina, SK S4P 0W5, Canada.
Email: bprasad@sasktel.net
C. **Consider giving a short acting antihypertensive agent prior to the hemodialysis session.** Certain antihypertensives such as captopril and hydralazine have rapid onset and offset and may be used to prevent intradialytic hypertension while not causing hypotension in between dialysis sessions.\(^{19}\)

D. **Choose antihypertensives that are less dialyzable.** Angiotensin converting enzymes, except for fosinopril, are highly dialyzable, whereas all angiotensin receptor blockers are non-dialyzable. Commonly used beta blockers such as metoprolol and atenolol are highly dialyzable\(^{20}\) while bisoprolol is moderately dialyzable and carvedilol is the least dialyzable.\(^{20}\) Nebivolol, another non-dialyzable beta-blocker, and irbesartan were effective in reducing intradialytic hypertension in one randomized trial.\(^{21}\)

E. **Consider lowering dialysate sodium.** In a small pre-post study (n = 50), reducing the dialysate sodium from 140 mmol/L to 136 mmol/L led to significantly lower third hour and post-HD SBP.\(^{22}\)

F. **Avoid high calcium dialysate.** As there is an association between lower calcium dialysate and lower post-HD systolic BP,\(^{23}\) a low-calcium dialysate is sometimes recommended to treat intradialytic hypertension. Strong evidence is lacking, however, and this approach may result in a negative calcium balance and increased risk of cardiac arrhythmias.\(^{24}\)

G. **Consider raising the dialysate temperature.** Lowering the dialysate temperature below core temperature increase intradialytic BP,\(^{25}\) while lower BPs are observed with higher dialysate temperatures.\(^{26}\)

H. **Consider switching administration of ESA to the subcutaneous route.** Intravenous ESA is associated with rises in mean arterial pressures 30 minutes after administration, and this effect can last up to 3 hours. Subcutaneous administration does not appear to have this effect.\(^{27}\)

**Acknowledgments**

Five things to know about . . . is an article type created and used by CMAJ and gratefully used by CJKHD with their permission.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iDs**

Bhanu Prasad [https://orcid.org/0000-0002-1139-4821](https://orcid.org/0000-0002-1139-4821)

Rita Suri [https://orcid.org/0000-0002-0519-3927](https://orcid.org/0000-0002-0519-3927)

**References**

1. Nongnuch A, Campbell N, Stern E, El-Kateb S, Fuentes L, Davenport A. Increased postdialysis systolic blood pressure is associated with extracellular overhydration in hemodialysis outpatients. *Kidney Int*. 2015;87(2):452-457.

2. Inrig JK. Intradialytic hypertension: a less-recognized cardiovascular complication of hemodialysis. *Am J Kidney Dis*. 2010;55(3):580-589.

3. Assimon MM, Wang L, Flythe JE. Intradialytic hypertension frequency and short-term clinical outcomes among individuals receiving maintenance hemodialysis. *Am J Hypertens*. 2018;31(3):329-339.
4. Kalainy S, Reid R, Jindal K, Pannu N, Braam B. Fluid volume expansion and depletion in hemodialysis patients lack association with clinical parameters. *Can J Kidney Health Dis*. 2015;2:54.

5. Inrig JK, Patel UD, Toto RD, Szczech LA. Association of blood pressure increases during hemodialysis with 2-year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and Mortality Wave 2 Study. *Am J Kidney Dis*. 2009;54(5):881-890.

6. Inrig JK, Oddone EZ, Hasselblad V, et al. Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients. *Kidney Int*. 2007;71(5):454-461.

7. Park J, Rhee CM, Sim JJ, et al. A comparative effectiveness research study of the change in blood pressure during hemodialysis treatment and survival. *Kidney Int*. 2013;84(4):795-802.

8. Agarwal R, Metiku T, Tegegne GG, et al. Diagnosing hypertension by intradialytic blood pressure recordings. *Clin J Am Soc Nephrol*. 2008;3(5):1364-1372.

9. Park J, Campese VM, Nobakht N, Middlekauff HR. Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. *J Appl Physiol* (1985). 2008;105(6):1873-1876.

10. Chaignon M, Chen WT, Tarazi RC, Nakamoto S, Bravo EL. Blood pressure response to hemodialysis. *Hypertension*. 1981;3(3):333-339.

11. Chou KJ, Lee PT, Chen CL, et al. Physiological changes during hemodialysis in patients with intradialysis hypertension. *Kidney Int*. 2006;69(10):1833-1838.

12. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW. Hypertension following erythropoietin therapy in anemic hemodialysis patients. *Am J Hypertens*. 1990;3(12, pt 1): 947-955.

13. Song JH, Lee SW, Suh CK, Kim MJ. Time-averaged concentration of dialysate sodium relates with sodium load and interdialytic weight gain during sodium-profiling hemodialysis. *Am J Kidney Dis*. 2002;40(2):291-301.

14. Ok E, Duman S, Asci G, et al. Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-center haemodialysis: a prospective, case-controlled study. *Nephrol Dial Transplant*. 2011;26(4):1287-1296.

15. Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. *Hypertension*. 2009;53(3):500-507.

16. Lacson E Jr, Xu J, Suri RS, et al. Survival with three-times weekly in-center nocturnal versus conventional hemodialysis. *J Am Soc Nephrol*. 2012;23(4):687-695.

17. Kotanko P, Garg AX, Depner T, et al. Effects of frequent hemodialysis on blood pressure: results from the randomized frequent hemodialysis network trials. *Hemodial Int*. 2015;19(3):386-401.

18. Inrig JK, Van Buren P, Kim C, Vongpatanasin W, Povsic TJ, Toto R. Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction. *Clin J Am Soc Nephrol*. 2012;7(8):1300-1309.

19. Bazzato G, Coli U, Landini S, et al. Prevention of intra- and postdialytic hypertensive crises by captopril. *Contriv Nephrol*. 1984;41:292-298.

20. Inrig JK. Antihypertensive agents in hemodialysis patients: a current perspective. *Semin Dial*. 2010;23(3):290-297.

21. Bikos A, Loutradis C, Angeloudi E, et al. The effects of nebivolol and irbesartan on postdialysis and ambulatory blood pressure in patients with intradialytic hypertension: a randomized cross-over study. *J Hypertens*. 2019;37(2):432-442.

22. Nair SV, Balasubramanian K, Ramasamy A, Thamizhselvam H, Gharla S, Periasamy S. Effect of low dialysate sodium in the management of intradialytic hypertension in maintenance hemodialysis patients: a single-center Indian experience [published online ahead of print March 18, 2021]. *Hemodial Int*. doi:10.1111/hdi.12921.

23. LeBeouf A, Mac-Way F, Utescu MS, et al. Effects of acute variation of dialysate calcium concentrations on arterial stiffness and aortic pressure waveform. *Nephrol Dial Transplant*. 2009;24(12):3788-3794.

24. Pun PH, Horton JR, Middleton JP. Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients. *Clin J Am Soc Nephrol*. 2013;8(5):797-803.

25. Mustafa RA, Bdair F, Akl EA, et al. Effect of lowering the dialysate temperature in chronic hemodialysis: a systematic review and meta-analysis. *Clin J Am Soc Nephrol*. 2016;11(3):442-457.

26. Sherman RA, Faustino EF, Berthol AC, Eisinger RP. Effect of variations in dialysate temperature on blood pressure during hemodialysis. *Am J Kidney Dis*. 1984;4(1):66-68.

27. Kang DH, Yoon KI, Han DS. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in hemodialysis patients. *Nephrol Dial Transplant*. 1998;13(11):2877-2883.